Expression of micro RNA-9 in Patients with Acute Myeloid Leukemia and its Impact on Treatment Strategy | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 28, Volume 72, Issue 2, July 2018, Page 4026-4033 PDF (458.53 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2018.9093 | ||||
 View on SCiNiTO | ||||
| Author | ||||
| 1Mona A. Ismail, 2Hanaa R.M. Attia, 1Mona H.I. Farag, 1Dalia A.D. El Dine Salem, 1Mysra S. Youssef | ||||
| 1Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, 2Department of Clinical Pathology, Medical Research Division, National Research Centre | ||||
| Abstract | ||||
| Background: Acute myeloid leukemia (AML) is a malignant disorder of hematopoietic tissue. It is one of the most common malignancies in adults. It is characterized by its heterogeneous and complex nature that includes chromosomal, genetic and epigenetic abnormalities. MicroRNAs have been described to be one of the epigenetic regulators in AML. Objective: The present study focused on measuring expression levels of miR-9 in de novo AML patients. 30 bone marrow samples were collected from patients attending at Hematology and Oncology Unit of Aldemerdash Hospitals.MiR-9 expression levels were measured using real time PCR. These expression levels were compared to 30 adult healthy volunteers. Patients and Methods: The present study was carried out in medical oncology and Clinical Pathology Departments of Ain Shams University and National Research Centre, Egypt during the period between September 2017 and April 2018. Results: Statistical analysis of the results showed that miR-9 was significantly down regulated in AML patients in comparison to controls. It is also significantly correlated to platelet count. Regarding diagnostic performance, this study showed that miR-9 has weak diagnostic performance but regarding screening function, it has perfect sensitivity but weak specificity so it can be used as an excluding test. Conclusion: This study showed reduction of miR-9 in bone marrow of AML patients and opened the horizon for future studies on diagnostic and screening performance of miR-9 to be performed on larger scale and different ethnic groups. | ||||
| Keywords | ||||
| Leukemia; myeloid; Acute; miR-9; treatment outcome | ||||
|
Statistics Article View: 165 PDF Download: 394 |
||||
